Lunai Bioworks Inc. (RENB) - 10-K Filing Summary
Business Context and Reporting Period
Company: Lunai Bioworks Inc. (formerly Renovaro Inc.)
Reporting Period: Fiscal year ended June 30, 2025
Business Model: Pre-clinical biotechnology and AI-driven healthcare technology company operating through three segments: Renovaro Biosciences (immunotherapies), Renovaro Cube (AI cancer diagnostics), and BioSymetrics (biomedical AI and drug discovery).
Recent Developments: The company changed its name from Renovaro Inc. to Lunai Bioworks Inc. in August 2025. It acquired BioSymetrics Inc. in April 2025 and Renovaro Cube in February 2024. In September 2025, an indirect subsidiary, Gedi Cube B.V., was declared bankrupt by the Court of Amsterdam.
Key Financial Metrics
| Metric | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(178,007,489) | $(88,425,828) |
| Operating Expenses | $188,966,002 | $81,639,296 |
| Cash and Cash Equivalents | $92,700 | $220,467 |
| Working Capital | $(28,109,502) | $(28,312,274) |
| Total Liabilities | $29,580,681 | $31,152,306 |
| Accumulated Deficit | $(510,462,570) | $(332,455,081) |
Debt Structure: The company holds various promissory notes and convertible notes, including bridge loans from related parties (Paseco ApS, Laksya Ventures) and secured notes. Interest rates range from 10% to 18%. As of June 30, 2025, notes payable totaled approximately $9.2 million (including related party notes).
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 101% to $178.0 million, primarily driven by a $170.4 million non-cash goodwill impairment charge related to the Renovaro Cube (RENC) reporting unit.
- Operating Expenses: Increased 131% to $189.0 million. While General and Administrative (G&A) expenses decreased by 27% and R&D expenses decreased by 80% due to cost-cutting and discontinued projects, these savings were overwhelmed by the goodwill impairment.
- Intangible Asset Impairment: Unlike the prior year which saw a $42.6 million impairment of intangible assets, no such impairment was recorded in 2025 as the carrying value was already zero.
- Cash Position: Cash decreased by $127,767 to $92,700, reflecting a net cash burn of $7.9 million from operating activities, partially offset by $8.4 million provided by financing activities (debt issuance and private placements).
Guidance, Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. With only $92,700 in cash and an accumulated deficit exceeding $510 million, the company requires substantial additional financing to fund operations for the next 12 months. Management plans to seek equity or debt financing, but no assurances are given.
Outlook: The company remains pre-revenue. Future success depends on raising capital to advance AI-driven diagnostics and immunotherapy candidates. The bankruptcy of Gedi Cube B.V. in September 2025 represents a material impairment and operational setback.
Key Risks:
- Liquidity Risk: Insufficient cash to fund operations without immediate capital raises.
- Legal Proceedings: The company is involved in multiple lawsuits, including securities class actions regarding the conduct of co-founder Serhat Gümüşkücü (who was convicted of fraud), shareholder derivative suits, and litigation against former partners (G Tech Bio/SRI) alleging falsified study results. A securities class action settlement was preliminarily approved in August 2025.
- Regulatory Risk: Products are pre-clinical or pre-commercial; regulatory approval is uncertain and costly.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of June 30, 2025, due to inadequate resources for complex accounting matters.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure immediate financing given the $92,700 cash balance and "substantial doubt" going concern warning.
- Legal Exposure: Review the status of the securities class action settlement and the outcome of the fraud litigation against former partners (G Tech Bio/SRI), which could result in significant liabilities or loss of IP.
- Goodwill Impairment: Assess the remaining value of the Renovaro Cube acquisition, given the $170 million impairment and the subsequent bankruptcy of its Dutch subsidiary.
- Debt Covenants: Examine the terms of the secured promissory notes (many held by related parties) to understand potential foreclosure risks or dilution upon conversion.
- Internal Controls: Monitor the company's progress in remedying the material weaknesses in internal controls over financial reporting.